Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.

[1]  J. Ravetch,et al.  Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies , 2011, Science.

[2]  J. Desjarlais,et al.  Antibody-Mediated Coengagement of FcγRIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus , 2011, The Journal of Immunology.

[3]  Min Xu,et al.  Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. , 2010, The Journal of clinical investigation.

[4]  G. A. Lazar,et al.  Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions , 2010, mAbs.

[5]  A. Kurosky,et al.  FcγRIIb Inhibits Allergic Lung Inflammation in a Murine Model of Allergic Asthma , 2010, PloS one.

[6]  Calman Prussin,et al.  IgE, mast cells, basophils, and eosinophils. , 2003, The Journal of allergy and clinical immunology.

[7]  L. Macchia,et al.  Omalizumab in severe allergic asthma: efficacy assessment by comparison of symptom score and peak expiratory flow values before and after therapy. , 2010, Journal of investigational allergology & clinical immunology.

[8]  D. Nemazee,et al.  Suppression of IgE B Cells and IgE Binding to FcεRI by Gene Therapy with Single-Chain Anti-IgE1 , 2009, The Journal of Immunology.

[9]  Holly M Horton,et al.  Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. , 2008, Cancer research.

[10]  G. A. Lazar,et al.  Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. , 2008, Molecular immunology.

[11]  J. Desjarlais,et al.  Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells , 2008, Molecular Cancer Therapeutics.

[12]  R. Crameri,et al.  Targeting the Extracellular Membrane-Proximal Domain of Membrane-Bound IgE by Passive Immunization Blocks IgE Synthesis In Vivo1 , 2008, The Journal of Immunology.

[13]  D. Greiner,et al.  Humanized SCID mouse models for biomedical research. , 2008, Current topics in microbiology and immunology.

[14]  J. Ravetch,et al.  Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.

[15]  Kenneth G. C. Smith,et al.  FcγRIIb controls bone marrow plasma cell persistence and apoptosis , 2007, Nature Immunology.

[16]  G. A. Lazar,et al.  A molecular immunology approach to antibody humanization and functional optimization. , 2007, Molecular immunology.

[17]  K. Calame,et al.  Regulation of plasma-cell development , 2005, Nature Reviews Immunology.

[18]  J. Ravetch,et al.  The inhibitory Fcγ receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells , 2005, Nature Immunology.

[19]  T. Yoshino,et al.  Roles of FcgammaRIIB in nasal eosinophilia and IgE production in murine allergic rhinitis. , 2004, American journal of respiratory and critical care medicine.

[20]  T. Casale,et al.  Omalizumab treatment downregulates dendritic cell FcεRI expression , 2003 .

[21]  C. Tunyaplin,et al.  Regulatory mechanisms that determine the development and function of plasma cells. , 2003, Annual review of immunology.

[22]  B. Heyman,et al.  Feedback regulation by IgG antibodies. , 2003, Immunology letters.

[23]  Charles A. Johnson,et al.  Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma , 2003, Current medical research and opinion.

[24]  Y. Durocher,et al.  High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. , 2002, Nucleic acids research.

[25]  T. Chang.  The pharmacological basis of anti-IgE therapy , 2000, Nature Biotechnology.

[26]  Salvi Ss,et al.  Treatment of allergic asthma with monoclonal anti-IgE antibody. , 1999 .

[27]  T. Yoshino,et al.  Modulation of Immunoglobulin (Ig)E-mediated Systemic Anaphylaxis by Low-Affinity Fc Receptors for IgG , 1999, The Journal of experimental medicine.

[28]  P. Jardieu,et al.  IgE Inhibition as a Therapy for Allergic Disease , 1999, International Archives of Allergy and Immunology.

[29]  L. Presta,et al.  Inhibition of allergic reactions with antibodies to IgE. , 1995, International archives of allergy and immunology.

[30]  L. Presta,et al.  Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release. , 1995, International archives of allergy and immunology.

[31]  L. Presta,et al.  The binding site on human immunoglobulin E for its high affinity receptor. , 1994, The Journal of biological chemistry.

[32]  L. Presta,et al.  Humanization of an antibody directed against IgE. , 1993, Journal of immunology.

[33]  J. Kinet,et al.  Identification of the low affinity receptor for immunoglobulin E on mouse mast cells and macrophages as Fc gamma RII and Fc gamma RIII , 1992, The Journal of experimental medicine.

[34]  F. Takizawa.  Identification of the low affinity receptor for immunoglobin E on mouse mast cells and macrophages as FcγRII and FcγRIII , 1992 .

[35]  D. Conrad,et al.  Characterization of new rat anti-mouse IgE monoclonals and their use along with chimeric IgE to further define the site that interacts with FcϵRII and FcϵRI , 1991 .

[36]  W. Hook,et al.  Monoclonal antibodies defining epitopes on human IgE. , 1991, Molecular immunology.

[37]  R. Geha,et al.  CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells , 1990, The Journal of experimental medicine.